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Background: Cancer mortality statistics for 2015 were projected from the most recent available data for the European
Union (EU) and its six more populous countries. Prostate cancer was analysed in detail.
Patients and methods: Population and death certiﬁcation data from stomach, colorectum, pancreas, lung, breast,
uterus, prostate, leukaemias and total cancers were obtained from the World Health Organisation database and Eurostat.
Figures were derived for the EU, France, Germany, Italy, Poland, Spain and the UK. Projected 2015 numbers of deaths
by age group were obtained by linear regression on estimated numbers of deaths over the most recent time period identi-
ﬁed by a joinpoint regression model.
Results: A total of 1 359 100 cancer deaths are predicted in the EU in 2015 (766 200 men and 592 900 women), corre-
sponding to standardised death rates of 138.4/100 000 men and 83.9/100 000 women, falling 7.5% and 6%, respective-
ly, since 2009. In men, predicted rates for the three major cancers (lung, colorectum and prostate) are lower than in 2009,
falling 9%, 5% and 12%. Prostate cancer showed predicted falls of 14%, 17% and 9% in the 35–64, 65–74 and 75+ age
groups. In women, breast and colorectal cancers had favourable trends (−10% and −8%), but predicted lung cancer
rates rise 9% to 14.24/100 000 becoming the cancer with the highest rate, reaching and possibly overtaking breast
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cancer rates—though the total number of deaths remain higher for breast (90 800) than lung (87 500). Pancreatic cancer
has a negative outlook in both sexes, rising 4% in men and 5% in women between 2009 and 2015.
Conclusions: Cancer mortality predictions for 2015 conﬁrm the overall favourable cancer mortality trend in the EU,
translating to an overall 26% fall in men since its peak in 1988, and 21% in women, and the avoidance of over 325 000
deaths in 2015 compared with the peak rate.
Key words: cancer, Europe, mortality, projections, prostate cancer, time trends
introduction
Estimates of cancer mortality statistics for the current year,
extrapolated from available data from a few years earlier, have
long been available for the United States [1], and have been re-
cently published for the European Union (EU), based on the
World Health Organisation (WHO) mortality database [2–5].
In 2012, we predicted that lung cancer mortality rates would
overtake those of breast cancer as the neoplasm with the highest
death rate in EU women in 2015 [4].
Here we provide ﬁgures for the year 2015 using the same
methodology, but including Croatia, which joined the EU in
2013, and data from the WHO mortality database updated in
February 2014 [6]. This report also focuses on prostate cancer,
which is the third cause of male cancer mortality in the EU [7].
materials andmethods
This work is an update to the previous articles on predicted European cancer
mortality, and is based on similar methods [2–5].
Ofﬁcial death certiﬁcation data for stomach, colorectum, pancreas, lung,
breast, uterus (cervix and corpus), prostate, leukaemias and total cancer (ma-
lignant and benign) mortality were obtained from the WHO database
(WHOSIS) [6]. Figures were derived for the EU (28 countries as of July
2013) in the period 1970–2009 and up to the most recent available year for
six major European countries: France (2010), Germany (2012), Italy (2010),
Poland (2011), Spain (2011) and the UK (2010). Details on data sources and
preparation are given in supplementary Appendix, available at Annals of
Oncology online.
From the matrices of certiﬁed deaths and resident populations, we com-
puted age-speciﬁc death numbers and rates for each 5-year age group (from
0–4 to 85+ years) and calendar year. Age-standardised rates per 100 000
men and women, at all ages, were computed using the direct method, based
on the world standard population [8]. For prostate cancer, rates for the 35–
64, 65–74 and 75+ years age groups were also computed.
We ﬁt a logarithmic Poisson count data joinpoint regression model to each
5-year age-speciﬁc number of certiﬁed deaths, and identiﬁed the most recent
trend segment (details in the supplementary Appendix, available at Annals of
Oncology online) [9]. We computed the predicted age-speciﬁc certiﬁed
numbers of deaths and the corresponding 95% prediction intervals (PIs) [10]
Table 1. Number of predicted cancer deaths and mortality rates for the year 2015 and comparison figures for most recent data for the EU as a whole,
with 95% prediction intervals
Observed
number of
deaths 2009
Predicted
number of
deaths 2015
Lower
prediction
limit (95%)
Upper
prediction
limit (95%)
Observed
ASRa 2009
Predicted
ASRa 2015
Lower
prediction
limit (95%)
Upper
prediction
limit (95%)
Sex Cancer 37 094 34 700 33 879 35 462 7.53 6.24 6.12 6.36
Men Stomach
Colorectum 88 953 95 900 94 531 97 320 17.51 16.57 16.28 16.87
Pancreas 37 069 42 700 41 910 43 482 7.87 8.15 7.99 8.30
Lung 185 656 191 900 188 801 194 961 39.59 35.98 35.35 36.60
Prostate 69 733 72 600 71 573 73 632 11.72 10.29 10.15 10.44
Leukaemias 22 240 23 600 22 883 24 221 4.67 4.12 3.96 4.27
All cancers
(malignant
and benign)
726 169 766 200 757 615 774 774 149.49 138.35 136.55 140.14
Women Stomach 24 317 21 200 20 401 21 988 3.46 2.73 2.61 2.85
Colorectum 75 904 76 700 75 361 78 052 10.19 9.36 9.19 9.53
Pancreas 37 054 42 600 41 951 43 306 5.34 5.62 5.53 5.71
Lung 74 350 87 500 86 094 88 883 13.05 14.24 13.97 14.52
Breast 90 412 90 800 88 983 9 2563 15.85 14.22 13.86 14.59
Uterus (cervix
and corpus)
27 937 28 500 27 882 291 37 5.03 4.69 4.57 4.81
Leukaemias 18 168 18 900 18 470 19 366 2.82 2.48 2.38 2.58
All cancers
(malignant
and benign)
569 099 592 900 586 290 599 523 89.29 83.93 82.96 84.90
aASR, standardised using the World Standard Population.
ASR, age standardised mortality rate.
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by performing a linear regression on mortality data from each age group over
the time period identiﬁed by the joinpoint model. Predicted standardised
death rates with 95% PI were then computed using the predicted age-speciﬁc
deaths numbers and the predicted population from Eurostat [11].
results
Table 1 shows total numbers (rounded to the nearest 100) of
cancer deaths and world standardised death rate predictions for
the EU in 2015 with corresponding 95% PIs, as well as the 2009
recorded data. A total of 1 359 100 Europeans are projected to
die of cancer in 2015; 766 200 men and 592 900 women. These
ﬁgures correspond to age-standardised rates of 138.4/100 000
men and 83.9/100 000 women. Thus, a 7.5% fall in rates for men
and a 6% fall in women are predicted, compared with data for
2009 (149.5 and 89.3/100 000, respectively, corresponding to
1 295 268 total deaths).
Figure 1A shows bar plots of standardised death rates per
100 000 population and certiﬁed death numbers for 2009 for EU
men and women, and the predicted values for 2015 with
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Figure 1. (A) Bar plots of age-standardised (world population) death rates per 100 000 and certiﬁed deaths for the year 2009 (green) and predicted rates and
number of deaths (predicted numbers of deaths are rounded to the nearest hundred) for 2015 (blue) with 95% prediction intervals (PIs) for total cancer mortal-
ity in the EU in men and women. (B) Bar plots of age-standardised death rates per 100 000 population for year 2009 (green) and predicted rates for 2015 with
95% PIs (blue) in the EU in men and women for selected cancer sites.
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corresponding 95% PIs. Figure 1B shows bar plots of age-stan-
dardised death rates for 2009 and 2015 predictions with 95% PIs
for the eight major cancer sites in EU men and women. Lung
cancer has the highest predicted rates in both sexes, in men 36/
100 000, corresponding to ∼191 900 predicted deaths (25% of
total male cancer deaths), and to a 9.1% fall in rates since 2009.
In women, mortality from this cancer is still rising and is pre-
dicted to become the neoplasm with the highest age-standar-
dised cancer mortality rate in the EU in 2015, with a predicted
rate of 14.24/100 000 (+9.2% since 2009), corresponding to
87 500 deaths (15% of total female cancer deaths) when com-
pared with 14.22/100 000 for breast cancer. However, the total
number of deaths remains higher for breast cancer (90 800).
Between the ages of 50 and 79 years, more deaths from lung
than breast cancer were predicted, while in elderly women an
excess in breast cancer deaths persisted.
Lung cancer is predicted to cause nearly 280 000 deaths in
both sexes combined in 2015, corresponding to over 20% total
cancer deaths. The cancer with the second largest impact is in-
testinal cancer (colon and rectum), with predicted rates of 16.6
and 9.4/100 000 in men and women, corresponding to 5.3% and
8.1% falls, respectively. Intestinal cancer deaths represent 13% of
total cancer deaths in the EU in 2015, with 172 600 projected
deaths. Breast cancer in women has the second highest projected
rate with a 10.2% fall from 2009, but the highest number of
deaths, while in men prostate cancer has the third highest pre-
dicted rate at 10.3/100 000 men with a 12.2% fall since 2009.
Pancreatic cancer shows rising predicted death rates in both
sexes (8.2 and 5.6/100 000 for men and women, 3.6% and 5.2%
rises, respectively), corresponding to 85 300 total deaths, that is
6% of all predicted cancer deaths. The remaining causes, cancer
of the uterus, stomach and leukaemias each represent <5% of
total cancer deaths, show recent declines and low age-speciﬁc
rates.
Figure 2 illustrates trends in standardised total cancer mortal-
ity rates for men and women in quinquennia centred from 1972
to 2007, and the predicted rates for 2015 with PIs. Trends in
total cancer mortality in the EU are favourable in both sexes;
in men rates have been falling since the late 1980s, while in
women they have been favourable over the entire period, though
recent falls were largest in men.
These favourable trends are seen in most of the studied
cancers in both sexes; in particular, stomach cancer mortality
shows the greatest falls over the whole studied period in both
sexes (Figure 3). In men, lung cancer also showed appreciable
falls in mortality since the late 1980s as did breast cancer in
women. The only exceptions to these generally favourable
trends in the EU are pancreatic cancer, whose mortality rates
have been showing steady rises in both sexes, and lung cancer in
women, which has shown strong rises over the whole studied
period becoming the cancer with the highest predicted mortality
rate in the EU for 2015. See supplementary Appendix, available
at Annals of Oncology online, with individual country data and
analyses (supplementary Tables S1–S9 and Figure S1, available
at Annals of Oncology online).
Table 2 shows age standardised mortality rates for prostate
cancer in the 2000–2004 and 2005–2009 quinquennia, their
percent difference and the predicted age standardised rate for
2015, for all ages, 35–64, 65–74 and the over 75 years age
groups, in the six studied countries and the EU as a whole. In
the early years of the new millennium, prostate cancer mortality
rates for all ages were between 10 and 15/100 000 men (Italy and
the UK, respectively), and showed favourable trends in all coun-
tries and the EU as a whole, giving predicted rates for 2015
between 7 (Italy) and 12/100 000 (Poland and the UK). The
overall decline between 2007 and 2015 approached 10%.
These patterns occur to a similar extent in subsequent age
groups: predicted rates for 2015 are between 2 and 8/100 000 in
35–64 year olds, 33 and 75/100 000 in the 65–74 years age group
and between 240 and 360/100 000 in men older than 75. In
2015, Poland and the UK have the highest predicted rates in all
age groups, while only in the 65–74 year olds Germany has a
slightly higher predicted rate than the UK but still lower than in
Poland. Between the two quinquennia, all trends were favour-
able, with the exception of men ≥75 in Poland. The predicted
rates for 2015 in the EU are favourable compared with 2009,
with values of 10.3, 4, 58.5 and 306.2/100 000 men for all ages,
35–64, 65–74 and over 75 years, respectively.
Figure 4 illustrates joinpoint analysis of prostate cancer age-stan-
dardised mortality rates for EU men in the four studied age groups,
with predictions for 2015 and relative PIs. All the age groups display
a similar pattern with rising trends up to the late 1980s–early 1990s,
where trends become favourable, all the age groups having an
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Figure 2. Age-standardised (world population) total cancer mortality rate
trends in quinquennia from 1970–1974 to 2005–2009 and predicted rates for
2015 with 95% prediction intervals (PIs), for men (squares) and women
(circles) in the EU.
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estimated annual percent change between −2% and −3% for the
most recent period.
discussion
In this study, we updated the EU dataset to include Croatia, and
the Eurostat population projections were also updated and
include a ﬁner age structure; hence, numbers of deaths and age-
standardised rates for the EU may differ slightly from previous
works and are not directly comparable [2–5, 11].
Due to their short-term nature and the large numbers
involved in their computation, the EU cancer mortality predic-
tions should not be affected by major random variation.
However, if a trend reversal were to have occurred within the
last few years, it is unlikely that this model would totally account
for it.
Due to population ageing, total numbers of cancer deaths are
predicted to rise up to 2015, in spite of decreasing age-standar-
dised cancer mortality rates [12]. There are ∼30% more male
cancer deaths, with a rate over 60% higher than that of women.
This excess mortality can be partly attributed to different
smoking pattern histories between men and women. However,
an alarming rise in the incidence of lung and other tobacco-
related cancers in women took place over the last two decades in
the EU [13, 14]. In women, lung cancer mortality rates have
been rising throughout the studied period in the EU, reaching
the predicted breast cancer rates (which have been falling stead-
ily) at 14.2/100 000, as suggested previously [4, 5, 13]. The
observation that lung cancer numbers of deaths overtook
those of breast cancer in middle-aged women indicates that, in
the absence of smoking cessation, these cohorts of European
women will maintain upward trends in lung cancer mortality
rates in the near future.
Conversely in men, lung cancer death rates have been
showing consistent downward trends in all the countries, reach-
ing a rate comparable with that recorded in the United States in
2010 (∼36/100 000) [15]. Lung cancer remains the ﬁrst site of
cancer death in EU men, and is also the most frequent cause of
cancer death in both sexes combined, accounting for over a ﬁfth
of all cancer deaths. Hence, tobacco, that accounts for over 80%
of lung cancers, is still the greatest determinant of cancer deaths
in the EU [16].
Stomach cancer has long been one of the main drivers for the
falls in mortality in both sexes, and has been showing consistent
falls throughout the studied period. These are probably due to
better diet and food conservation, as well as a fall in Helicobacter
pylori infection prevalence [17–19]. Colorectal cancer was the
second cause of cancer mortality overall, and has been showing
favourable trends in both the EU as a whole and the individual
studied countries with the exceptions of Spanish and Polish men.
These favourable trends are likely due to improved diagnostic and
therapeutic practices [20–23].
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Figure 3. Age-standardised (world population) EU male and female cancer mortality rate trends in quinquennia from 1970–1974 to 2005–2009 and predicted rates
for 2015 with 95% prediction intervals (PIs). Men: stomach (squares), colorectum (circles), pancreas (triangles), lung (crosses), prostate (xs) and leukaemias (inverted
triangles). Women: stomach (squares), colorectum (circles), pancreas (triangles), lung (crosses), breast (xs), uterus (diamonds) and leukaemias (inverted triangles).
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Table 2. Age-standardised prostate cancer mortality rates for all ages, 35–64, 65–74 and 75+ years in the quinquennia 2000–2004 and 2005–2009 with percentage differences and predicted total rates in
the EU and selected countries
All ages 35–64 years 65–74 years 75+ years
ASRa
2000–
2004
ASRa
2005–
2009
% Difference
2000–2004
versus 2005–
2009
Predicted
ASRa 2015
ASRa
2000–
2004
ASRa
2005–
2009
% Difference
2000–2004
versus 2005–
2009
Predicted
ASRa 2015
ASRa
2000–
2004
ASRa
2005–
2009
% Difference
2000–2004
versus 2005–
2009
Predicted
ASRa 2015
ASRa
2000–
2004
ASRa
2005–
2009
% Difference
2000–2004
versus 2005–
2009
Predicted
ASRa 2015
Men
France 14.43 12.11 −16.11 9.08 5.34 4.60 −13.89 4.50 81.35 67.31 −17.25 33.49 435.26 365.62 −16.00 300.56
Germany 13.78 11.96 −13.22 10.92 5.93 5.42 −8.64 4.86 82.72 73.74 −10.86 69.71 390.23 329.55 −15.55 296.28
Italy 10.35 8.88 −14.16 7.48 3.50 3.00 −14.12 2.39 57.75 48.47 −16.07 39.03 317.98 276.15 −13.16 238.83
Poland 13.21 13.02 −1.42 12.16 6.57 6.21 −5.44 7.61 89.44 87.74 −1.89 74.65 334.55 335.03 0.14 303.20
Spain 12.06 10.05 −16.68 8.60 4.27 3.63 −14.93 3.51 66.16 56.76 −14.21 34.59 371.20 303.99 −18.11 288.73
United
Kingdom
15.42 14.05 −8.86 12.32 6.17 5.46 −11.49 6.12 94.23 85.19 −9.60 65.41 439.78 404.87 −7.94 357.69
European
Union
(28)
13.76 12.21 −11.25 10.29 5.53 4.95 −10.49 4.01 81.47 72.97 −10.43 58.50 398.22 351.18 −11.81 306.15
aASR standardised using the World Standard Population.
ASR, age standardised mortality rate.
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Pancreatic cancer is the only major cancer showing unfavour-
able trends in both sexes. This neoplasm has a very low survival
rate (5% at 5 years). Pancreatic cancer aetiology is still largely
unaccounted for, since smoking (the main identiﬁed risk factor)
is responsible for ∼30% of cases, while obesity, diabetes, family
history and high alcohol intake barely account for another 10%
of cases [24].
Breast cancer has the highest projected rates for women in
most of the examined countries, the exceptions being the UK and
Poland that had very high lung cancer rates. Breast cancer has
had a favourable trend since the late 1980s/early 1990s, likely due
to improved therapeutic procedures and screening [25]. Thus, in
the EU overall, breast is no longer the cancer site with the highest
projected rate in 2015, having a lower rate than lung cancer.
Leukaemias and uterine cancers both show favourable trends,
due to continuous improvements in treatment [26].
Predicted trends for prostate cancer in the EU were favourable
throughout subsequent age groups, and trends have been down-
ward since the late 1980s/early 1990s, but showed appreciable
variation between countries, with the highest rates in the UK
being over 50% higher than those of Italy for all ages. This
cancer is amenable to treatment and the role of screening prac-
tices is still debated, even though favourable mortality trends
support a relevant role [27, 28]. The observed falls in mortality
are of similar magnitude in various age groups up to ≥75 years,
indicating that appreciable advancements in prostate cancer
management have been achieved for the elderly too. The falls in
rates were smaller in Poland than in Western European coun-
tries, stressing the importance of adopting modern management
and treatment protocols for prostatic cancer in Central and
Eastern Europe [27].
Total cancer mortality has shown favourable trends in both
sexes throughout the EU, and differences between countries can
be largely attributed to differences in lung cancer mortality for
both sexes, and hence to historic differences in smoking habits.
Exception to the general favourable trends were German, Italian
and Spanish women, where a plateau may have been reached. In
these countries, the rise in female lung and pancreatic cancer
rates is not offset by the favourable trends of other sites.
To summarise, predicted cancer mortality for the EU shows
continuing favourable trends in both sexes, similarly to the
United States [1, 15]. Since the 1988 mortality peak, over
325 000 deaths will be avoided for 2015 alone when compared
with 1988 rates. However, the mortality differential between
Western European countries and former non-market economy
ones remains, and the unfavourable trends in female lung
cancer and pancreatic cancer in both sexes are worrying. Hence
a stronger effort is required on implementing anti-tobacco pol-
icies (particularly for women), and on improving cancer man-
agement in Central and Eastern Europe.
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Figure 4. Annual prostate cancer age-standardised (world population) death rates in the EU per 100 000 for all ages, 35–64, 65–74 and over 75 years age
groups from 1970 to 2009, the resulting joinpoint regression models, and predicted rates for the year 2015 with 95% PIs. On the left, men all ages (full squares)
and men 35–64 years (empty squares), on the right men 64–75 years (full squares) and men over 75 years (empty squares).
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